Dupilumab-Associated Head and Neck Dermatitis With Ocular Involvement in a Ten-Year-Old With Atopic Dermatitis: A Case Report and Review of the Literature

Arthur M Samia; Lyda Cuervo-Pardo; Marjorie E Montanez-Wiscovich; Vanessa Y Cavero-Chavez

doi:10.7759/cureus.27170

Dupilumab-Associated Head and Neck Dermatitis With Ocular Involvement in a Ten-Year-Old With Atopic Dermatitis: A Case Report and Review of the Literature

Cureus. 2022 Jul 23;14(7):e27170. doi: 10.7759/cureus.27170. eCollection 2022 Jul.

Authors

Arthur M Samia¹, Lyda Cuervo-Pardo², Marjorie E Montanez-Wiscovich³, Vanessa Y Cavero-Chavez⁴

Affiliations

¹ Dermatology, University of Florida, Gainesville, USA.
² Allergy and Immunology, University of Florida, Gainesville, USA.
³ Dermatology, University of Florida College of Medicine, Gainesville, USA.
⁴ Pediatrics, University of Florida, Gainesville, USA.

Abstract

Facial and neck erythema secondary to dupilumab use is a side effect not reported in clinical trials; however, it has been reported aftermarket initially in adults and most recently in adolescents. We report the youngest known case of head and neck dermatitis (HND) secondary to Malassezia furfur accompanied by ocular involvement. Treatment with oral fluconazole 150 mg weekly was initiated with subsequent cutaneous improvement. Additionally, his conjunctivitis improved with fluorometholone 0.1% eye drops. As dupilumab becomes more accessible to children, understanding the pathophysiology of HND, characterizing the clinical course, and developing diagnostic and treatment guidelines for this age group will be imperative.

Keywords: atopic dermatitis; child; conjunctivitis; dupilumab; monoclonal antibodies.

Publication types

Case Reports